LABÈGE, France, September 03, 2024 / Biotech Newswire / -- Antabio, a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens, with a particular focus on life-threatening respiratory infections, today announced that it has completed the Phase 1 clinical trial for MEM-ANT3310 in healthy volunteers.
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections. MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor that provides a unique coverage of priority Gram-negative pathogens including OXA-carbapenem-resistant Acinetobacter baumannii (CRAB), KPC- and OXA- carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa (PA).
The Phase 1 clinical trial included 72 healthy volunteers across three parts and evaluated the safety, tolerability, and pharmacokinetic (PK) profile of Single and Multiple Ascending Doses (SAD/MAD) of the intravenous beta-lactamase inhibitor ANT3310, administered alone. The potential mutual PK interaction between ANT3310 and meropenem was investigated, followed by an assessment of the combination MEM-ANT3310 during multiple intravenous dosing.
ANT3310 was well-tolerated at all doses with no serious adverse events, dose-limiting toxicities or clinically relevant abnormalities reported. The ANT3310 PK parameters were consistent with those determined from studies in rodent and non-rodent species and dose-dependent increases in exposure were observed. ANT3310 and meropenem demonstrated very compatible PK with no mutual PK interaction.
This positive Phase 1 data supports further patient studies of MEM-ANT3310.
“With matching PK and good tolerability, MEM-ANT3310 shows great promise to address serious infections whenever multidrug resistance is a concern in hospitalized patients.” said Marc Lemonnier, CEO of Antabio. “With a uniquely broad coverage, we believe MEM-ANT3310 will be very well positioned to meet the urgent medical needs in high-risk patients, especially when multidrug-resistant pathogens or polymicrobial infections are suspected”.
Antabio is currently conducting a Phase 1 PK study of MEM-ANT3310 in subjects with impaired renal function and is planning a second PK study to assess the distribution of MEM-ANT3310 in the lung (epithelial lining fluid) in healthy volunteers.
About MEM-ANT3310
Carbapenems such as meropenem are the cornerstone of therapies for many life-threatening infections. Resistance to carbapenems is considered a critical priority by the World Health Organisation (WHO) and Centre for Disease Control and Prevention (CDC) because it is a major cause of treatment failure, increased mortality, and huge economic costs.
Bacteria resistant to carbapenems produce β-lactamase enzymes that render antibiotics, such as meropenem, ineffective. ANT3310 inhibits a broad range of β-lactamases, including the Klebsiella pneumoniae carbapenemases (KPC) and oxacillin-hydrolysing (OXA) type enzymes found in Carbapenem-Resistant Enterobacterales (CRE) and most importantly Carbapenem-Resistant Acinetobacter baumannii (CRAB). The combination of this potent β-lactamase inhibitor with the antibiotic meropenem (MEM-ANT3310) therefore provides a critical solution for the treatment of serious infections that may be caused by MDR pathogens, such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
MEM-ANT3310 has received qualified infectious disease product (QIDP) status from the FDA in 2020 for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and HABP and VABP.
About Antabio
Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. The company’s lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). Antabio’s portfolio includes additional innovative preclinical programs addressing areas of highest unmet need in the antibacterial space.
Contact
Antabio
Marc Lemonnier, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Clinical Trial, Phase I; Bacterial Infections; Anti-Bacterial Agents; Meropenem; Carbapenems; carbapenemase; Oxacillin; beta-Lactamase Inhibitors; Klebsiella pneumoniae; Pseudomonas aeruginosa; Acinetobacter baumannii; Drug Resistance, Bacterial; beta-Lactamases; Monobactams; Pseudomonas Infections; Respiratory Tract Infections; Hospitals; Pneumonia, Bacterial; Ventilators, Mechanical; Healthcare-Associated Pneumonia; Pseudomonas aeruginosa; Pneumonia, Ventilator-Associated; Biological Products; France; Antabio; MEM-ANT3310; Phase 1 Clinical Study; Severe Hospital Infections; Antibacterial treatments; Antimicrobial resistance; Carbapenem-resistant; Meropenem (MEM); Serine-beta-lactamase (SBL) inhibitor; Gram-negative pathogens; OXA-carbapenem-resistant Acinetobacter baumannii (CRAB); Carbapenem-resistant Enterobacterales (CRE); Pseudomonas aeruginosa (PA); Multidrug-resistant pathogens; Polymicrobial infections; Hospital-acquired bacterial pneumonia (HABP); Ventilator-associated bacterial pneumonia (VABP); Qualified Infectious Disease Product (QIDP); Complicated urinary tract infections (cUTI); Complicated intra-abdominal infections (cIAI); Nosocomial pneumonia; Chronic pulmonary diseases; Drug-resistant infections
Source: Biotech Newswire